Gewinn- und Verlust: Viking Therapeutics, Inc.

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $27.88, denoting a +1.86% move from the preceding trading day.

Viking Therapeutics trades at yearly lows despite being ahead of recently acquired competitor Metsera in the weight-loss drug race. The Metsera deal suggests up to 150% upside to Viking, especially when compared to Pfizer's $7.2 billion buyout price, including milestone CVRs. VKTX's oral and injectable weight-loss drugs show promising results, with Phase 3 trials already ongoing and potential to outperform Metsera.

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.09, indicating a -5.78% shift from the previous trading day.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $24.97, denoting a -4.88% move from the preceding trading day.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 11:20 AM EDT Company Participants Brian Lian - President, CEO & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2023 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Brian Lian - President and CEO Greg Zante - CFO Stephanie Diaz - Manager of IR Conference Call Participants Joon Lee - Truist Steven Seedhouse - Raymond James Jay Olson - Oppenheimer. Naz Rahman - Maxim Group.

The late investing legend Charlie Munger talked about a "fat-pitch strategy," a baseball analogy about waiting for a big, no-brainer opportunity you can take advantage of. When you get that fat pitch, it's a chance to get a home run.

Investing in biotechnology stocks is complex due to the science behind the company's drug candidates. They can be difficult to trade because these stocks are highly volatile, with double-digit moves in both directions a common occurrence.